Monday 9/14 a.m. — Desk Preview

Prepared Sunday 9/13/26. Landscape only, no recommendations.

The frame

This is about as thin as the earnings calendar gets between seasons — nothing on the before-the-open slate carries broad index weight, so the tape's attention Monday morning is really on the macro setup into Wednesday's FOMC. The S&P closed Friday at 7,656.98 (+65 on the day) even as the 10-year presses 4.975%, within a hair of 5% and at a 52-week high, after Friday's hot-ish August CPI (headline +0.4% m/m/3.4% y/y, core +0.3%, gasoline +3.9%). Fed funds futures are pricing roughly 70-90% odds of a 25bp hike to 3.75-4.00% under Chair Kevin Warsh, whose hawkish Jackson Hole tone flipped the September meeting from a hold to a hike; the July meeting itself held with three dissents in favor of hiking. VIX at 15.84 says the options market isn't stressed about it, but WTI at $102.43 on the Iran re-escalation and gold at $4,379 both argue the crosscurrents (rates up, oil up, gold up) are real. Last week's read-through matters here too: Oracle's OCI beat got punished on RPO deceleration nuance, Adobe's in-line print with light guidance was sold, and Copart missed outright — the tape is paying only for clean, unblemished prints right now, which sets a high bar for anything reporting Monday. Against that backdrop, Monday's before-the-open names are mostly small- and micro-cap idiosyncratic stories (crypto-asset management, defense/industrial niche names, a distressed food company) that will trade on their own numbers rather than move the market, but they're useful tells on risk appetite in the margins.

Tier 1 — before the open

CSHR CoinShares ($5.36) — first H1 print as a Nasdaq-listed pure-play crypto asset manager. CoinShares confirmed via press release that it will publish first-half 2026 results before the open Monday, with a call at 8:30 am ET (1:30 pm BST). Consensus for the quarter runs to roughly $0.09 EPS on about $28.3 million of revenue, per Yahoo estimates. Market cap is $706 million, forward P/E near 12x, and short interest is light at 1.1% of float — this isn't a name with a crowded short base or squeeze mechanics attached. The stock trades within a wide 52-week range of $3.51-$10.43, reflecting how tightly CSHR is levered to crypto-asset prices and flows into its funds rather than any standalone operating story; the read-through here is less about CSHR itself and more a sentiment gauge on institutional crypto engagement heading into a week where risk appetite is already being tested by the rate backdrop. What to watch on the call: assets under management trend, fee margin, and any commentary on U.S. listing dynamics now that it trades domestically alongside its London listing.

HAIN Hain Celestial ($0.62) — distressed micro-cap staples name reporting fiscal Q4/full-year 2026. Hain confirmed a before-the-open release Monday with an 8:00 am ET call. Consensus sits at roughly -$0.03 EPS on $269 million of revenue for the quarter. The stock's own chart tells the story: a $56 million market cap and a 52-week range of $0.48-$1.80 make this one of the more washed-out names reporting all week, and at these levels the print is as much about balance sheet and covenant commentary as it is about the organic-food category itself. Short interest of 6.4% is moderate, not extreme, for a stock this beaten down. What to watch: any refinancing or liquidity commentary, category-level volume trends in its natural/organic portfolio, and whether management reiterates or walks back prior full-year guidance given the persistent misses that got the stock here.

The rest, by cluster

The remaining before-the-open names are small-cap industrials and niche tech that will trade almost entirely on their own numbers. RF Industries ($10.32, $112 million market cap, consensus $0.20 EPS/$23.3 million revenue, 7.8% short interest) is a wire-and-cable/interconnect name whose print is a minor tell on telecom and data-center infrastructure capex at the smallest end of that supply chain — worth a glance given how central data-center capex is to the week's bigger AI-infrastructure debate, even though RFIL itself is far too small to move that needle. Coda Octopus ($10.02, $113 million market cap, consensus $0.115 EPS/$7.3 million revenue) is a niche marine/sonar technology name trading near the top of its 52-week range ($7.80-$17.28 — actually mid-range), with modest 2.3% short interest; nothing here suggests positioning for a surprise either way. Immersion ($7.40, $246 million market cap, consensus $0.055 EPS/$3.4 million revenue, 7.8% short interest) is a haptics-licensing royalty story — its results are a function of legal/licensing cadence more than end-market demand. ZenaTech ($1.52, $135 million market cap, consensus -$0.22 EPS/$9.2 million revenue, 11.1% short interest) is a small drone name still in cash-burn mode; Waldencast ($1.31, $168 million market cap, consensus -$0.17 EPS/$65.4 million revenue) is a foreign-private-issuer beauty-brands roll-up reporting H1 results — treat its filing cadence and disclosure format as a 6-K-style report rather than a standard 10-Q.

Where the asymmetries sit

HAIN is the one name in this batch that's genuinely washed-out rather than merely small — a stock down roughly 65% from the top of its 52-week range going into the print, where the options market (to the extent it's liquid at this market cap) is likely pricing tail risk on both sides: either a stabilization narrative that sparks a relief bounce off a depressed base, or confirmation of the negative spiral that keeps pressuring it toward the low end of its range. CSHR sits at the other end of the spectrum — not washed-out, but a name whose 52-week range implies it trades on crypto beta more than on its own fundamentals, so Monday's print is unlikely to be the primary driver of the stock either way. Nothing in this batch carries meaningful squeeze mechanics; short interest across the group tops out at ZenaTech's 11.1%, which is elevated for a small-cap but not the kind of extreme positioning that turns a beat into a violent short-covering move.

Dominoes

The direct read-throughs from this a.m. batch to the rest of the week are limited given the size of the names, but there are two threads worth tracking. First, RFIL's small-cap infrastructure print is a minor data point in the broader "is AI/data-center capex still accelerating or plateauing" debate that's been live since Oracle's OCI beat got sold last week on RPO-growth nuance — any commentary on order backlog or lead times from RFIL adds a small brick to that wall either way. Second, HAIN's results, and any commentary on private-label pressure, tariff-driven input costs, or consumer trade-down in the natural/organic aisle, sit adjacent to the broader consumer-bifurcation theme that's shown up in recent guide-cuts from LULU, Tyson, and Chewy — a continuation of that pattern here would reinforce the read that lower-income and value-conscious consumer spending is still deteriorating into the holiday season, a theme that matters more for retail-sensitive names later in the week and beyond.

Flagged as unverified

Coda Octopus's 52-week range as sourced ($7.80-$17.28) sits above the current $10.02 quote by a wide margin on the low end and doesn't square cleanly with a stock supposedly trading mid-range; the range should be treated as approximate pending a direct check of the ticker. Waldencast reports as a foreign private issuer on an H1 basis rather than a standard U.S. fiscal quarter — comparability of its "consensus" figures to a typical U.S. small-cap print is uncertain and was not independently verified against a named data provider. Short-interest and float figures for RFIL, CODA, IMMR, ZENA, and WALD were taken from the data provided rather than independently re-verified this session.

Sources: CoinShares investor relations (investor.coinshares.com) and GlobeNewswire press release; Hain Celestial investor relations (ir.hain.com), Nasdaq press-release syndication, and StockTitan; general market levels from prior verified data (S&P, Nasdaq, Dow, VIX, 10-year, WTI, gold, DXY, August CPI) as supplied; Oracle/Adobe/Copart reaction context as supplied.

Monday 9/14 p.m. — Desk Preview

Prepared Sunday 9/13/26. Landscape only, no recommendations.

The frame

The after-the-close slate is dominated by one name with genuine broad interest — Dave & Buster's — sitting alongside a handful of small- and micro-cap prints that will trade on their own tape. That's the story of this whole week: a thin calendar between seasons, with the macro frame doing more work than usual. The S&P closed Friday at 7,656.98, up 65 points, even with the 10-year at 4.975% and pressing its 52-week high, after a slightly hot August CPI (core +0.3% m/m) that pushed Fed-funds-futures odds of a 25bp hike Wednesday to roughly 70-90% under Chair Kevin Warsh. VIX at 15.84 is calm, but WTI at $102.43 (Iran re-escalation), gold at $4,379, and a 10-year knocking on 5% all argue for caution. The tape's recent behavior is the key context for Monday evening: Oracle, Adobe, and Copart all reported last week, and the market punished any blemish — Oracle's OCI beat was sold on RPO deceleration nuance, Adobe's in-line quarter was sold on light guidance, and Copart missed outright. That sets a demanding bar for Dave & Buster's, a name already sitting at its 52-week low with heavy short interest, reporting into a market that has shown zero patience for anything short of a clean beat-and-raise.

Tier 1 — after the close

PLAY Dave & Buster's ($8.14) — the marquee print of the session, a turnaround story reporting at its 52-week low. Dave & Buster's confirmed it will report second-quarter fiscal 2026 results (quarter ended August 4, 2026) after the close Monday, with a call at 4:00 pm CT (5:00 pm ET). Consensus estimates for the quarter vary meaningfully by source — one dataset shows roughly $0.19 EPS while Yahoo's own earnings-calendar page separately shows $0.92, a gap wide enough that it should be treated as unreconciled rather than as a single consensus number; last year's comparable quarter (Q2 FY25) EPS was $0.40. The prior quarter (Q1 FY26, reported June 15) is the more reliable anchor: revenue of $559.2 million, down 1.5% year-over-year, on a comparable-store-sales decline of 5.4% (management attributed part of that to a spring-break calendar shift), with GAAP EPS of $0.16 (adjusted $0.22) versus $0.62 GAAP ($0.76 adjusted) a year earlier — a sharp year-over-year profit decline. The one number that mattered inside that otherwise soft print was food & beverage same-store sales, up roughly 5% and positive for nine straight months, and free cash flow of $25 million, an $84 million swing from negative $59 million a year prior. Management guided on that call that second-quarter comps had already improved to roughly a 4% decline despite unfavorable weather, and cited early remodel data showing a 7% comp uplift at roughly half the historical remodel cost — the two data points the market will be checking Monday for continuation. The company is under CEO Kevin Sheehan's "back to basics" turnaround, explicitly reversing what he has called overly aggressive and confusing changes to marketing, menu, remodels, and game investments made by prior management; the balance sheet itself is not the worry here — the company describes low leverage, no near-term debt maturities, and no operative financial covenants — but the pace of capital return has slowed sharply, from roughly $172 million of buybacks in fiscal 2024 to about $24 million in fiscal 2025 to date, itself a signal of a more conservative capital posture. The stock is at its 52-week low of $8.14 against a 52-week high of $24.99 — down roughly two-thirds from that high — with a market cap of just $283 million. Short interest is heavy by any measure, though sources disagree on the exact level: the figure supplied for this note is 32% of float, while a separate short-interest tracker (Fintel) shows a more recent reading near 45%; either way this is a stock with a large short base into the print, which raises the odds of an outsized reaction (in either direction) on any surprise, clean or otherwise. What to watch on the call: whether the comp trend actually continued improving into Q2, whether food & beverage same-store growth held its streak, any update on remodel ROI and pace, and any fresh commentary on debt, buybacks, or the broader turnaround timeline.

KMTS Kestra Medical Technologies ($22.85) — high-growth wearable-defibrillator story, first fiscal quarter of a new year. Kestra confirmed it will report first-quarter fiscal 2027 results after the close Monday, with a call at 4:30 pm ET. This is a 2025 IPO still in the steep part of its growth curve: revenue ran $19.4 million in Q1 FY26 (+52% y/y), $22.6 million in Q2 FY26 (+53% y/y), and $24.6 million in Q3 FY26 (+63% y/y), with gross margin expanding each quarter — from 45.7% to 50.6% to 52.6%. Consensus for the quarter reporting Monday is roughly $29.0 million of revenue against -$0.625 EPS; the implied year-over-year growth rate versus last year's $19.4 million base would be a still-strong but decelerating pace in the high-40s percent. Market cap is $1.34 billion against roughly $100 million of trailing annual revenue, a rich multiple that leaves little room for a growth disappointment — this is a name priced for continued execution, not for a slowdown. Short interest of 9.5% is moderate for a richly valued recent IPO. What to watch: revenue growth rate versus the deceleration embedded in consensus, gross-margin trajectory (whether the multi-quarter expansion streak continues), and any commentary on reimbursement or competitive dynamics in the wearable cardiac-defibrillator space.

ANAB AnaptysBio ($53.87) — struck from Monday's slate: the Q2 print already landed 9/2. Some calendars (Yahoo, and the sheet this note was built from) still carry AnaptysBio for Monday after the close, but the company put out its second-quarter results and business update on September 2, so there is no fresh print Monday. It stays on the radar only as positioning context — 40.7% of the float is short and the stock has ranged $11.40-$72.36 over 52 weeks as it converted itself into a Jemperli/imsidolimab royalty vehicle — and any Monday move would be news- or flow-driven rather than earnings-driven.

UROY Uranium Royalty Corp ($4.36) — nuclear-cycle royalty name; date also appears to conflict with this slate. Consensus for the quarter is roughly $0.069 EPS, a swing to profitability from a prior-quarter loss, against a 52-week range of $2.56-$5.52 and a $1.66 billion market cap. Separately sourced coverage indicates Uranium Royalty may have already reported results in the prior week (around September 10-11), with options pricing at the time implying only a modest ~2% move — which would mean, if accurate, that Monday's listing on this calendar is stale and the actual print has already been absorbed by the tape. This should be confirmed before treating Monday as a live catalyst for the name. To the extent it (or aftermarket commentary) does land this week, the story is a read on nuclear-fuel-cycle sentiment and uranium spot/term prices, a theme that has been running hot on renewed nuclear-power demand narratives tied to data-center electricity needs — a direct link to the power/grid bottleneck theme running through the AI infrastructure debate.

PLCE Children's Place ($2.43) — distressed apparel retailer; date also flagged as uncertain. Consensus for the quarter is roughly -$0.93 EPS on $268 million of revenue. The trend line here is ugly: the prior quarter reportedly missed badly, posting a loss of $1.52 per share against an estimated $0.08 loss, with revenue of $242 million well short of a $314 million estimate. Trailing twelve-month EPS is deeply negative, debt-to-equity is elevated, and current and quick ratios both point to real liquidity strain. Short interest is very high at 43.8% of float, and the stock trades near the bottom of a $2.04-$9.56 52-week range. Separately, some sourcing places the next earnings date at Tuesday 9/15 rather than Monday — a discrepancy worth confirming before positioning around a specific session. As a read-through, PLCE sits squarely in the consumer-bifurcation theme that's shown up recently in LULU's guide cut, Tyson's outlook reduction, and Chewy's guidance trim — another weak print here would extend the pattern of value/lower-income consumer spending deteriorating into the back-to-school and holiday windows.

RLGT Radiant Logistics ($8.13) — fiscal Q4 and full-year numbers land with the 4:30 pm ET call. Radiant set its investor call for Monday 9/14 at 4:30 pm ET to walk through the fourth fiscal quarter and year ended June 30, 2026; the results release itself had not appeared as of Sunday, so the numbers and the call should arrive together. Consensus is roughly $0.09 EPS on $231 million of revenue, short interest is a modest 2.2% of float, and the stock sits mid-range across a $5.78-$9.68 52-week band. Founder/CEO Bohn Crain's commentary on freight-forwarding volumes, pricing, and demand — plus the pace of the tuck-in acquisition program — is the relevant read for the broader industrial/logistics tape, since freight volumes track underlying goods demand closely.

The rest, by cluster

HKD AMTD Digital ($1.69, $531 million market cap) reports H1 results as a Cayman-domiciled foreign private issuer — treat any headline "consensus" comparison with caution given thin analyst coverage and a filing structure that differs from a standard U.S. 10-Q. HITI High Tide ($2.53, $222 million market cap, consensus $0.02 EPS/$195 million revenue) is a Canadian cannabis retailer, also a foreign filer, whose print is more a read on Canadian cannabis retail volumes than a U.S. market signal. USAU U.S. Gold Corp ($15.20, $251 million market cap, consensus -$0.42 EPS, 9.7% short interest) is a pre-revenue-stage gold developer whose quarterly loss is largely a function of exploration and permitting spend rather than an operating story, trading within a $12.23-$23.75 range. At the very small end, MindWalk Holdings ($1.31, $61 million market cap) and Bioceres ($0.42, $27 million market cap) round out the tail — both too small to carry index-level signal, worth only a passing check for anyone with a direct position.

Where the asymmetries sit

PLAY is the clearest asymmetry on the board this week: a stock down two-thirds from its 52-week high, carrying a large short base by any reading of the data, reporting into a tape that has shown zero tolerance for blemished beats over the past week. That combination — heavily shorted, priced for continued deterioration, but with early internal data (food & beverage comps, remodel ROI) suggesting the turnaround has some traction — sets up a binary-feeling event even though the underlying business change is incremental. PLCE carries the kind of short interest (43.8% of float) where a clean beat, or even an in-line quarter with no new bad news, can force outsized covering moves independent of the fundamental magnitude of the surprise. KMTS sits at the opposite pole — a growth story priced for perfection, where the risk sits more in a deceleration surprise than in a beat, given a market cap that already assumes the current growth trajectory continues.

Dominoes

PLAY's print is this week's cleanest test of whether the market will reward a genuine sequential improvement (comps, food & beverage, FCF) even when the headline numbers remain soft in absolute terms — directly relevant to how the tape treats the rest of the thin calendar this week, and a data point for the broader "is the consumer bifurcating" thread running alongside LULU, Tyson, and Chewy's recent guide cuts. PLCE, if its numbers do land this week, reinforces or complicates that same thread from the distressed end of apparel retail. UROY and the uranium/nuclear angle connect to the power-and-grid-bottleneck theme that underlies the AI-capex debate — nuclear demand narratives are increasingly cited as a solution to data-center power constraints, so continued strength in uranium royalty economics is a soft, indirect confirmation of that thesis. KMTS's growth deceleration or acceleration is a read on how much room is left in high-multiple medtech growth names broadly, relevant context heading into a week where rate direction (post-FOMC Wednesday) will matter disproportionately for long-duration, high-multiple growth stocks — KMTS sits squarely in that rate-sensitive bucket given its valuation relative to current earnings.

Flagged as unverified

PLAY's current-quarter EPS consensus is internally inconsistent across sources ($0.19 vs. $0.92 on Yahoo's own calendar page) and was not reconciled; treat any single-point EPS consensus for PLAY with caution. PLAY's short interest is sourced two ways — 32% of float per the data supplied for this note, versus a more recent Fintel reading near 45% — the true current figure is unconfirmed. ANAB is a stale calendar entry — the company reported Q2 on 9/2 — and has been removed from Monday's stats table. UROY's Monday listing likewise conflicts with coverage suggesting it reported the prior week (around 9/10-9/11); if so, Monday is not a fresh catalyst for this name. PLCE's date also shows a conflict, with some sourcing pointing to Tuesday 9/15 rather than Monday. RLGT's release timing is inferred from the 9/8 call announcement (results were not yet public as of Sunday); if the numbers post before Monday's session, the call becomes a discussion of known figures rather than a fresh print. HKD and HITI are foreign private issuers reporting on non-10-Q filing schedules (H1/foreign-filer format); consensus comparisons for both carry more uncertainty than for standard U.S. filers.

Sources: Dave & Buster's investor relations (ir.daveandbusters.com), GlobeNewswire, StockTitan, and Motley Fool/Globe and Mail earnings-transcript coverage for Q1 FY26 detail; restaurant-trade coverage (Restaurant Business, Restaurant Dive, FSR Magazine, CX Dive) on the "back to basics" turnaround; Fintel and TipRanks/the Fly coverage referenced for PLAY short interest and implied-move context; Kestra Medical investor relations (investors.kestramedical.com), BioSpace, and StockTitan for KMTS; AnaptysBio investor relations (ir.anaptysbio.com) and Investing.com earnings coverage for ANAB; Cerbat Gem, Investing.com, and Nasdaq earnings-calendar coverage for UROY; Investing.com, TipRanks, and Nasdaq earnings-calendar coverage for PLCE; StockTitan and MarketBeat for RLGT's release/call-date split; general market levels as supplied.

Tuesday 9/15 a.m. — Desk Preview

Prepared Sunday 9/13/26. Landscape only, no recommendations.

The frame

Tuesday is FOMC day one — Warsh and the committee are sequestered while the market runs on positioning rather than news, with fed funds futures putting 70-90% odds on a 25bp hike to 3.75-4.00% at Wednesday's 2pm decision. That backdrop dwarfs a genuinely thin earnings slate: the only two names with real size before the bell are FPS and VRA, both micro-to-mid-cap and both carrying idiosyncratic stories (a power-infrastructure re-rate and a distressed-retail turnaround) that are unlikely to move the tape but will be closely watched inside their own names. With the 10-yr pressing 5% and Friday's hot CPI print still digesting, risk appetite into the print is thin; the options market in FPS is pricing an outsized single-stock move (~15%) that is far larger than anything else on the calendar this morning.

Tier 1 — before the open

FPS Forgent Power Solutions ($31.82) — power-equipment re-rate testing its first full-quarter print since the post-IPO unwind. Forgent makes electrical distribution gear for data centers, the power grid, and heavy industrial sites (switchgear, transformers, automatic transfer switches, eHouses) — a direct proxy for Carl's power/grid-bottleneck thread. Consensus for fiscal Q4 (ended June 30) sits near $0.22 EPS on roughly $430M of revenue; the options market is pricing close to a 15% move. The prior quarter (Q3 FY26, reported August) was a blowout on paper — revenue +103% y/y to $379M, adjusted EBITDA +96% to $85M, adjusted net income +132% to $55M, bookings up 308% y/y to $867M, backlog up 157% y/y to $1.98B — and management raised full-year guidance across the board (revenue to $1.35-1.39B, adjusted EBITDA to $310-320M). The stock popped double digits on the print itself, then round-tripped and then some: an upsized secondary priced July 1-2 (~43.65M shares at $49, a steep discount to the prior close, with Neos Partners-affiliated holders selling alongside ~11.3M primary shares) hit the stock hard, and the standard IPO lockup expiring August 4 added a second wave of selling pressure. Short interest reportedly surged over 90% in June to roughly 12.85M shares. Net effect: the stock is down roughly 50% from its June 22 all-time high of $66 even as the underlying growth story (backlog conversion, book-to-bill, margin trajectory) hasn't obviously broken — which is exactly the tension the print needs to resolve. Watch for: backlog growth and book-to-bill (is demand still outrunning supply, or is this the top of the power-capex cycle Carl's been probing), gross margin trajectory as volumes scale, any commentary on how much of the backlog is data-center-driven versus utility/industrial, and whether guidance for fiscal 2027 gets set at a level that can absorb a slower AI-capex growth rate. Consensus sell-side view remains bullish (average rating "Strong Buy," average target well above spot), but that itself is a data point — a beat-and-raise that doesn't reignite the stock would say more about position-cleansing (dilution overhang, short covering exhaustion) than about the business.

The rest, by cluster

VRA Vera Bradley ($3.14) reports fiscal Q2 2027 before the open, with consensus at -$0.08 EPS on $66.0M of revenue. The prior quarter (Q1 FY27, reported June 11) was the turnaround's first genuine green shoot: revenue +7.8% y/y to $55.7M — the first overall revenue growth since Q4 FY22 — non-GAAP gross margin up 430bp to 51.8%, and operating loss narrowed 76% y/y to $3.3M, driven by the "Project Sunshine" cost and merchandising overhaul (indirect-channel sales up sharply, direct up modestly). Full-year guidance calls for an EPS loss of roughly -$0.34 with revenue near $263M, with management pointing to a return to profitability in fiscal 2028. Short interest is modest (3.5% of float) and the stock sits mid-range of its 52-week band ($1.39-$4.39). Watch for whether Q1's revenue inflection held for a second quarter — one quarter of growth after four years of decline is not yet a trend — and whether gross-margin gains (largely freight/duty and mix driven) are durable as tariff-related input costs work through, a direct read on the consumer-bifurcation/tariff-pass-through thread.

Tail cluster: MWC (Micware, Japan), NAMM (Namib Minerals, small-cap gold producer — H1 2026 results are due around this date; FY2025 EBITDA was $29.0M with 2026 EBITDA guidance of $50-62M at a $4,500/oz gold assumption), WSHP (WeShop) and CTRM (Castor Maritime) round out the morning slate but carry limited liquidity and thin coverage. NAMM and CTRM in particular are foreign private issuers that file on 6-K/20-F schedules rather than 10-Q, so headline comparability to US GAAP peers should be treated cautiously; none of the four is expected to move broader tape.

Where the asymmetries sit

FPS is the clean asymmetry setup of the morning: a name where the fundamental growth story (backlog, bookings, margin) has continued to run hot while the stock has been mechanically pressured by supply (secondary, lockup unwind) rather than by any change in the demand picture — the kind of gap that a clean beat-and-raise, or conversely a soft backlog number, could close quickly given the size of the short base and the options-implied move. VRA is a smaller, slower-moving asymmetry: the market has not re-rated the turnaround aggressively (stock still near the low end of its 52-week range), so a second consecutive quarter of revenue growth and margin expansion would be confirmation rather than surprise, while a relapse would validate the market's skepticism.

Dominoes

A soft FPS print or cautious commentary on data-center power demand would reinforce the "peak AI capex" thread that's been building since the Oracle/Adobe reactions last week (where the market punished any blemish and paid only for clean raises) and would likely spill into sentiment on other grid/power-equipment names (Powell Industries, Vertiv, and the broader electrical-equipment complex) given how thin the coverage universe is. A clean beat that still fails to hold the stock up would be read as evidence that the supply overhang (short interest, post-lockup float) is the dominant force, independent of fundamentals. On the FOMC side, any hawkish leak or repositioning ahead of Wednesday's decision would likely overwhelm single-stock moves in both FPS and VRA by midday.

Flagged as unverified

The FPS ~15% options-implied move figure comes from a single aggregator citation and could not be independently cross-checked against a live options chain; treat as directional only. Exact short-interest percentage of float for FPS as of the most recent settlement date (vs. the June share-count figure found) was not independently confirmed. NAMM's H1 2026 results release date and content could not be confirmed as of this writing despite the company's earlier-stated H1 reporting timeline. WSHP and MWC company descriptions and any estimates for their reports were not independently verified beyond their presence on Tuesday's earnings calendar.

Sources: Investing.com, StockTitan, WallStreetZen, MarketBeat, Tickeron, The Motley Fool, Yahoo Finance, SEC EDGAR (Forgent Power Solutions 8-K/10-Q filings), stockanalysis.com.

Tuesday 9/15 p.m. — Desk Preview

Prepared Sunday 9/13/26. Landscape only, no recommendations.

The frame

Tuesday's after-the-close slate is headlined by Trip.com, the week's one genuinely large-cap print, landing on the same day the FOMC begins its two-day meeting (decision Wednesday 2pm ET). That sequencing matters: China-outbound-travel and consumer data will hit tape hours before the Fed acts, so any TCOM reaction Tuesday night and Wednesday morning will trade alongside — and could be overwhelmed by — positioning into the rate decision. The macro setup remains tight: 10-yr at 4.975% and pressing 5%, WTI at $102.43 on the re-escalating Iran conflict, VIX still low at 15.84 despite Friday's hot CPI, and fed funds futures pricing 70-90% odds of a 25bp hike to 3.75-4.00%. A hike that size, delivered alongside a hawkish dot plot from Chair Warsh, would validate the tightening the market has already priced since Jackson Hole; anything less hawkish reopens a relief-rally conversation that's been closed off since July. For Wednesday's session specifically, Tuesday's FOMC day-one positioning typically means thin, directionless trade with volume concentrated in rate-sensitive sectors (homebuilders, already at 52-week lows on the 5% 10-yr; regional banks; long-duration growth) as the market waits out the blackout period before the actual decision — TCOM's reaction, EPM's smallcap-E&P read-through on $100+ crude, and the broader tape will all likely take a back seat to rate positioning until 2pm Wednesday.

Tier 1 — after the close

TCOM Trip.com Group ($39.02) — the session's marquee print, sitting near a 52-week low with the China-travel bear case in full voice. Consensus for Q2 2026 (three and six months ended June 30) is roughly RMB 5.74 per ADS in non-GAAP EPS (Yahoo's estimate convention; a USD-equivalent consensus was not independently confirmed — flagged below) on revenue of roughly RMB 15.6B, translating to roughly $2.1-2.2B by other estimates; management's own guidance framed the quarter as net revenue growth of approximately 3-8% y/y, a sharp deceleration from Q1's "exceptionally strong" comparison base. The prior quarter (Q1 2026, reported June 24) was a split print: revenue beat (RMB16.2B, +17% y/y, about 2.3% above consensus) but non-GAAP EPS missed by roughly 6.7% ($5.73 vs. ~$6.14 expected) on higher sales-and-marketing spend (adjusted S&M up 24% y/y); the stock fell over 4% after-hours to a level near its 52-week low. Since then the stock has continued to slide — now roughly half its 52-week high near $79 and sitting just above the 52-week low of $38.04 — on a combination of a China State Administration for Market Regulation antitrust probe (with an associated RMB 3.5B fine and RMB 1.6B confiscation reportedly weighing directly on Q2 results), intensifying competition from Meituan, Douyin, and Fliggy in both hotel and flight booking (rivals gaining share as the antitrust scrutiny constrains Trip.com's promotional flexibility), and — per Carl's macro thread — a re-escalating Iran conflict and higher fuel costs pressuring outbound travel demand generally. Sell-side price targets have been cut materially: one tracked "fair value" estimate fell from roughly $77 to $62, though headline analyst targets still cluster in the $71-97 range, well above spot — a gap that itself says the sell-side has not fully capitulated on the long-term China-travel-recovery thesis even as it has repeatedly trimmed near-term numbers. Short interest is low (2.0% of float), suggesting the move down has been long-side de-risking rather than an aggressive short squeeze setup. Watch the call for: the magnitude and duration of the antitrust-related fine/confiscation impact (one-time versus recurring), international/outbound booking growth trends given the Iran-conflict overhang, take-rate and marketing-spend trajectory as competition intensifies, and any commentary on U.S.-listed ADR risk given the broader China-ADR delisting overhang. This reports via 6-K as a foreign private issuer, not a 10-Q — flag for the EDGAR watcher.

EPM Evolution Petroleum ($3.72) — a smallcap E&P read on whether $100+ crude is actually showing up in producer numbers. Consensus for fiscal Q4 (ended June 30) is $0.01 EPS on $23.2M revenue; the print comes after the close with a conference call the next morning. Zacks' own framing going in was for a y/y earnings decline, a reminder that hedging programs and legacy-asset decline curves can mute a small producer's leverage to a crude spike even at $102 WTI. Short interest sits at 8.9% of float per the data used for this preview, though a separate source (~2.35% of float) was found in research and could not be reconciled — flagged below. The stock trades in the bottom half of its 52-week range ($3.19-$5.70). Watch for: production volumes and decline-curve trends on the company's core (largely non-operated) assets, realized pricing versus WTI/Henry Hub benchmarks, hedge book positioning into a higher-price environment, and any capital-return or acquisition commentary — this is a low-torque name, so the read-through value is more about whether smallcap E&P as a group is capturing the current crude/gas price environment than about EPM specifically.

The rest, by cluster

No other names of consequence are scheduled after Tuesday's close; the after-hours session is a two-name affair (TCOM, EPM) bracketing a market that will already be positioning for FOMC day two.

Where the asymmetries sit

TCOM is the clearer asymmetry: a stock down roughly 50% from its high, with consensus already reset lower for regulatory drag and slowing growth, against sell-side targets that (despite recent cuts) still imply significant upside — meaning the print needs to show either that the antitrust overhang is genuinely episodic (bullish gap-closing risk) or that competitive share loss to Meituan/Douyin is structural (bearish case that the targets above spot are stale and due for another leg of cuts). EPM carries much less asymmetry — a small, thinly-covered name where the crude-price tailwind is real but diluted by hedges and decline curves, so surprises in either direction are likely to be modest in magnitude even if directionally clean.

Dominoes

A weak TCOM print or cautious guidance on Chinese outbound travel would likely pressure the broader China-travel and consumer-discretionary ADR complex (Meituan, JD, Alibaba travel-adjacent exposure) heading into a week already thin on offsetting catalysts, and would compound Thursday's Hang Seng weakness already visible in JD Logistics, Meituan, and Kuaishou. A clean EPM beat with constructive commentary on realized pricing would be a modest positive data point for the smallcap E&P group generally, reinforcing the idea that $100+ crude is filtering through to producer economics — relevant context for anyone tracking the energy-equity lag versus the spot-crude move. Most importantly, both prints land inside the FOMC blackout-adjacent window, so any reaction is likely to be provisional until the Wednesday 2pm decision and Warsh press conference reset the macro tape.

Flagged as unverified

A precise USD-consensus EPS/revenue figure for TCOM's Q2 2026 (versus the RMB-denominated Yahoo estimate) could not be independently confirmed. An options-implied move for TCOM into the print was not found in available sources. The claimed magnitude of the SAMR antitrust fine/confiscation's direct impact on Q2 results (RMB 3.5B fine, RMB 1.6B confiscation) comes from a single secondary source and was not cross-checked against a Trip.com filing. EPM's short-interest figure is inconsistent across sources (8.9% vs. a separately found ~2.35% of float) and could not be reconciled as of this writing; the $8.9%/float figure is used above per the data set provided for this preview. EPM's most recent traded price found via one aggregator ($5.04) differs from the Friday 9/11 closing print used here ($3.72); the latter is used as the basis for this note but the discrepancy could not be resolved.

Sources: SEC EDGAR (Trip.com Group 6-K filings), Investing.com, PR Newswire, StockTitan, Yahoo Finance, Simply Wall St, GuruFocus, stockanalysis.com, GlobeNewswire.

Wednesday 9/16 a.m. — Desk Preview

Prepared Sunday 9/13/26. Landscape only, no recommendations.

The frame

Wednesday stacks a full macro sequence on top of an unusually thin earnings tape. August retail sales lands at 8:30am ET, roughly five and a half hours before the FOMC statement at 2:00pm and Chair Kevin Warsh's press conference at 2:30pm, which also carries an updated dot plot / Summary of Economic Projections. Going in: S&P 500 closed Friday 9/11 at 7,656.98 (+65 on the day), the 10-year is pressing 5% at 4.975% (a 52-week high), VIX sits a complacent 15.84, WTI is $102.43 on the re-escalating Iran conflict, gold $4,379, and DXY 99.15. August CPI printed hot on Friday — headline +0.4% m/m / 3.4% y/y, core +0.3% m/m, both a tenth above where the Street wanted them, with gasoline +3.9% m/m doing real work. Fed funds futures are pricing roughly 70-90% odds of a 25bp hike to 3.75-4.00% Wednesday, with December pricing implying a live possibility of a second hike before year-end — a full reversal from where the market sat before Warsh's hawkish Jackson Hole remarks flipped the September meeting from "hold" to "hike," and July's decision already carried three dissents in favor of hiking. Friday 9/18 is quad witching, which will start bleeding into positioning as the week goes on. Against that backdrop, Wednesday's actual earnings slate is two small-caps before the open — LuxExperience (LUXE) and Ispire Technology (ISPR) — plus thin pre-market tail names. Neither is macro-moving; the frame for the day is set by retail sales and the Fed, not by these prints. A tape that's already punishing beats with any blemish and paying only for clean raises makes the macro half of the day the more important variable even for names that don't report.

Tier 1 — before the open

LUXE ($7.39) — the luxury-turnaround story reports fiscal Q4 with the bar already set low. LuxExperience (the former Mytheresa, now combined with Net-a-Porter/Mr Porter and Yoox after the 2025 NET-A-PORTER/YOOX-NET-A-PORTER deal) reports before the open with an 8am ET call, covering the fiscal year ended June 30. Consensus is for a loss of $0.09/share on $633M of revenue; market cap is $1.01B against a 52-week range of $6.54-11.38, so the stock is roughly in the lower half of that band. The prior two quarters built a specific narrative: Mytheresa net sales +9.9% on a constant-currency basis on a "fewer, better" high-value-customer focus, while Net-a-Porter/Mr Porter sales fell 5.1% and Yoox fell 7.4% — but both of the declining segments posted meaningfully better gross margins (Yoox +620bps) as promotions were pulled back. Management has reaffirmed medium-term targets of €4B net sales and 7-9% adjusted EBITDA margin with a return to 10-15% growth, and has now posted positive adjusted EBITDA for two consecutive quarters. The metric that matters Wednesday is whether that margin-over-volume trade continues to hold across all three brands into the June quarter, or whether the NAP/Yoox revenue declines are still decelerating enough to keep the "transformation plan on track" framing intact. As a luxury-consumer read, it's a useful cross-check against how affluent U.S. and European spending is holding up into a higher-for-longer rate backdrop — relevant to Carl's consumer-bifurcation thread even though LUXE itself is European-listed and thinly followed by U.S. sell-side.

ISPR ($1.49) — small-cap vape hardware name reporting fiscal Q4 after a rough prior quarter. Ispire reports before the open with an 8am ET call, covering the fiscal year ended June 30; consensus is $0.015 EPS on $21.3M revenue, against a $86M market cap and 52-week range of $1.01-3.87. The prior quarter (fiscal Q3, March quarter) was messy: revenue fell to $18.7M from $26.2M a year earlier and from $20.3M sequentially, partly seasonal (Chinese New Year factory downtime) but gross margin also cratered to 10.7%, hit by $2.2M of one-time returns tied to severing a legacy cannabis-vape customer relationship. Management's pitch since has centered on the Malaysia manufacturing base (a claimed 25% tariff advantage over China-made product) and "Age-Gating" authentication technology as the unlock for the $50-70B U.S. flavored-vape market pending regulatory clearance. The metric that matters is whether revenue snaps back toward the $21.3M consensus and gross margin recovers off the 10.7% trough; the tariff-advantage and age-gating regulatory commentary on the call are the framing points, not the headline EPS, given the rounding-error size of the numbers.

Yahoo also lists Here Group (HERE/QSG) and QSG-adjacent names among Wednesday's pre-market tail. Here Group (the former QuantaSing, now largely a pop-toy business after divesting its education/livestreaming segment) most recently cut full-year guidance to RMB600-610M from RMB750-800M citing weak demand — a thin, idiosyncratic name with no real macro read-through.

The rest, by cluster

Outside LUXE and ISPR there is effectively no other domestic earnings of size before the open Wednesday — this is genuinely a between-seasons week. Both reporting names are small-cap, thinly covered, and low-float-sensitive rather than index-moving; the closest thing to a cluster read is "consumer discretionary at the margin" — LUXE on the luxury/affluent side, ISPR on the low-end/regulatory-driven vape side — but neither is liquid enough to move sector ETFs on its own.

Where the asymmetries sit

The real asymmetry Wednesday morning is macro, not single-stock: retail sales at 8:30am is the last data point before a live, still-not-fully-priced FOMC decision, and a hot or cold surprise there can move the hike/no-hike odds meaningfully in the few hours before 2pm. On the two earnings names, LUXE has already told the market to expect a loss and to look past headline revenue for margin trend — the asymmetry is a clean-margin beat getting rewarded even on soft top-line, versus any slippage back into promotional discounting getting punished hard given how thin the float is. ISPR's small size and history of one-time charges means its print carries outsized percentage-move risk in either direction relative to its news content.

Dominoes

A hot retail sales print reinforces the hike case building since Jackson Hole and could push December second-hike odds higher into the FOMC statement; a soft print complicates the decision just hours before the Fed acts and raises the odds of a more contentious dot plot with more dissents. Whatever the Fed delivers at 2pm/2:30pm sets the mortgage-rate and discount-rate backdrop that Lennar reports directly into after the close the same day — the a.m. macro sequence is effectively the setup for the p.m. earnings event. Quad witching Friday 9/18 is two trading days out and will start showing up in options positioning and pinning behavior as the week progresses.

Flagged as unverified

Could not find options-implied move data for LUXE or ISPR, or confirmed short-interest figures for either name. The exact consensus figure for August retail sales m/m is unclear — search results returned conflicting numbers (one citing an expected 0.8% decline, another describing 2026 retail sales as accelerating to the year's strongest pace), so no specific consensus number is used above; treat the print as a genuine swing input rather than a formality. Could not independently confirm Here Group/QSG's exact Wednesday reporting status beyond being listed as a pre-market tail name by Yahoo. LUXE's most recent quarterly stock reaction (% move on the last print) was not verified.

Sources: Yahoo Finance, StockTitan, LuxExperience investor relations (investors.luxexperience.com), PR Newswire/Ispire Technology press releases, Investing.com, CNBC, The Motley Fool, MarketBeat, stocktitan.net (QSG/HERE).

Wednesday 9/16 p.m. — Desk Preview

Prepared Sunday 9/13/26. Landscape only, no recommendations.

The frame

The p.m. slate is dominated by one name reporting directly into the tape the FOMC just repriced. Lennar releases fiscal Q3 results after the close roughly two hours after the 2pm rate decision and thirty minutes after Warsh's 2:30pm press conference and dot plot — meaning the stock trades all session on hike/hold odds and Fed-communication tone, then reports into whatever level that leaves it at. Context: 10-year at 4.975% and pressing 5%, 30-year mortgage averaging 6.76% as of the week of 9/11 (up from 6.71% the week before), fed funds futures pricing roughly 70-90% odds of a 25bp hike to 3.75-4.00%, and homebuilders already sitting near 52-week lows — ITB $89.54 versus a 52-week high of $115.26, XHB $98.46 versus $123.13. If the Fed hikes and Warsh's tone leans hawkish on the dot plot, mortgage-sensitive names like Lennar report into a fresh leg higher in real rates on the same day; if the statement or press conference reads more balanced, LEN gets some relief into the print. Either way, the sequencing — hike decision, then presser, then LEN two hours later — is the defining structural feature of Wednesday, not a coincidence to gloss over. Four smaller names round out the after-the-close slate: Rezolute (RZLT), Espey (ESP), Aeluma (ALMU), and Sangoma (SANG).

Tier 1 — after the close

LEN ($79.60) — the print of the week, reporting straight into the post-FOMC tape. Lennar reports fiscal Q3 (August quarter) after the close, with the call held the next morning (9/17, 11am ET). Consensus is $1.30 EPS on $8.37B revenue; against the $2.00 EPS Lennar posted a year ago, that's roughly a 35% y/y decline, and consensus sits almost exactly at the midpoint of the company's own June guidance range of $1.20-1.40. Deliveries are guided to 20,500-21,500, average sales price to $375,000-380,000, gross margin to approximately 16%, and SG&A to 8.8-9% — so consensus is essentially betting the company hits its own numbers with little room for a beat or miss on the guided range itself. The prior quarter (Q2 FY26, reported June 11) came in largely in line: 20,519 deliveries within guidance, 21,749 new orders near the high end of guidance, gross margin of 15.6% (a sequential improvement), and — the one data point the Street cared about most — the incentive load falling to 12.9% of sales from 14.1% in Q1 and 14.5% in Q4 FY25, an early signal that the "volume over margin" / even-flow strategy was starting to work without further margin give-back. Despite that in-line quarter, Lennar simultaneously cut its full-year 2026 delivery target to 82,000-83,000 homes, citing rate pressure and macro/geopolitical uncertainty, and the stock has continued grinding toward 52-week lows since. The tension for Wednesday: Q3 guidance calls for gross margin to improve sequentially to ~16% even as EPS craters 35% y/y — the one metric that matters is whether that margin guide holds, or whether Lennar has to lean harder on incentives again with mortgage rates rising into the print (30-year at 6.76% and climbing, tracking the 10-year toward its own 52-week high). The stock at $79.60 sits about 4% off its 52-week low of $76.63 and roughly 43% below its 52-week high of $139.44, with a fairly rich forward P/E context of 12.4x on depressed estimates. Short interest is only 0.24% of float — this is not a crowded short setup; the de-rating has been a long-only unwind, not squeeze-driven, so there's no mechanical short-covering bid to cushion a miss. Options pricing (per Bloomberg-compiled data cited by Investing.com) points to roughly a 5.2% one-day expected move, though a separate read of the options chain around the $78 level with implied vol near 42 suggests a one-standard-deviation move closer to 8-9%; notably, the stock has exceeded its options-implied move in four of the last eight quarterly prints (e.g., -10.9% in March against a 5.2% implied move, and -6.8% last September against a 5.8% implied move) — the desk read is that premium has tended to underprice how violently LEN actually trades on print day. Sell-side has moved with the stock rather than ahead of it: since the June print, UBS cut FY26 EPS estimates to $5.80 from $6.65 (FY27 to $7.80 from $9.30), KBW cut its target to $85 from $86 (Underperform, citing gross margin cuts to 15.7-15.9%), RBC cut to $85 from $88 (Underperform, weak demand), and Wells Fargo cut to $80 from $85 (Equal Weight) — all clustering close to spot, which reads as the Street having largely caught down to the stock rather than seeing a floor beneath it. The land-light Millrose Properties spin-off (completed February 2025, moving roughly $6B / 105,000 homesites of land assets off Lennar's balance sheet) remains a background structural question the market has been probing through 2026 — whether the web of land-banking relationships tied to Millrose creates disclosure gaps the expanded SEC filings and Q2 call commentary haven't fully closed. On the call, watch: delivery and order cadence into a rising-rate tape, whether the incentive rate keeps falling or has to reverse, the ASP trend against the $375-380k guide, buyback pace, any explicit management read on the Fed decision that landed hours earlier and its effect on mortgage demand, and the durability of the even-flow strategy generally. Read-through is direct and immediate: KBH, TOL, DHI, PHM, and NVR all trade off Lennar's incentive/margin data point for point, as does the building-products chain (BLDR, HD, LOW). Toll Brothers' luxury book is viewed as more insulated from rate-sensitive buyers, PulteGroup screens with the group's best gross margin (26.1%) and lowest leverage (0.21x net debt/EBITDA), Builders FirstSource already cut its 2026 outlook with single-family starts guided down mid-to-high single digits, and Lowe's cut FY26 comp-sales guidance to flat with Q3 EPS seen down roughly 7% y/y — a soft incentive/margin data point from Lennar would read across the whole complex the next session, layered on top of whatever the Fed just did to mortgage rates.

The rest, by cluster

Binary/high-short-interest small-caps: Rezolute ($4.22, mcap $406M, EPS est -$0.14, short interest 26.6% of float, 52-week range $1.07-11.46) reports fiscal Q4 after the close, but the number itself is close to irrelevant — the 52-week range tells the real story. The stock's high traces to before December 11, 2025, when the Phase 3 sunRIZE trial of lead candidate ersodetug in congenital hyperinsulinism missed its primary endpoint (a self-monitored-blood-glucose measure of hypoglycemia events), and the stock crashed roughly 89% in a single session, from a $10.94 close to briefly trading near $1.23-1.40. A March 2026 FDA Type B meeting reportedly produced unusually constructive feedback, with the agency acknowledging weaknesses in the SMBG-based endpoint and requesting the fuller CGM-based dataset for review — the stock has since rebuilt to $4.22, roughly tripling off the post-crash low but still far below the pre-crash high. The real catalyst remains the separate Phase 3 upLIFT trial (tumor hyperinsulinism), with topline data guided for H2 2026; a 26.6% short interest signals the stock is positioned around that binary readout, not the quarterly loss-per-share number. Aeluma ($13.41, mcap $245M, EPS est -$0.075, rev est $0.6M, short interest 27.8%, 52-week range $10.24-31.79) is a similar story-stock setup: a photonics/sensor semiconductor name levered to the AI-datacenter optical-interconnect narrative, with full fiscal-year 2026 revenue guided at only $4.0-6.0M — meaning the quarterly consensus is a rounding error against the thesis. It reports after the close with a 5pm ET call; with short interest near 28% of float, any datacenter-customer or qualification-program update carries outsized asymmetric move risk independent of the financial results.

Steady-state small-cap prints: Espey Manufacturing ($63.69, mcap ~$170M, forward P/E 17.2, EPS est $0.96, rev est $14.8M, 52-week range $36.00-74.77) reports fiscal Q4 (June quarter) for its defense power-electronics business. In the year-ago fiscal Q4, net sales fell to $9.6M from $11.6M but net income rose to $2.93M ($1.05 diluted EPS) from $1.89M ($0.73) — a margin-expansion-on-lower-volume pattern the Street will be watching to see repeat. This is a thinly covered name with minimal options or short-interest data available. Sangoma Technologies ($3.70, mcap $123M, EPS est -$0.07, rev est $51.3M, 52-week range $3.40-6.46) reports fiscal Q4 for its UCaaS/communications-infrastructure business; note it files as a Canadian foreign private issuer (40-F/6-K rather than 10-K/10-Q). The prior quarter (fiscal Q3, reported May) missed on revenue — C$51.0M versus a C$52.08M estimate — with gross margin compressing to 71% from 74% sequentially, and management trimmed full-year FY26 revenue guidance to C$204-205M with adjusted EBITDA margin guided to 15-16% as spending shifts toward infrastructure and AI-enabled segments. The question Wednesday is whether Q4 stabilizes that guide-down trend or extends it.

Where the asymmetries sit

Lennar is the clear focal point: with short interest at just 0.24% of float, a disappointing print is a long-only de-rating rather than a short squeeze, and the options market's ~5.2% implied move looks light against a stock that has moved further than that in half of its last eight quarterly reports — asymmetry favors a larger-than-priced reaction in either direction, compounded by reporting hours after a live Fed decision that directly moves the mortgage-rate variable in Lennar's own guidance. Among the smaller names, Rezolute and Aeluma both carry standalone binary risk from short interest above 25% of float — for either name, a headline unrelated to the quarterly numbers (an FDA update for RZLT, a customer/qualification update for ALMU) could swamp the print itself.

Dominoes

Whatever gross margin and incentive data Lennar delivers reads directly into KBH, TOL, DHI, PHM, NVR and the building-products chain (BLDR, HD, LOW) the next session — this is a same-day macro-to-single-stock-to-sector chain: FOMC decision and dot plot at 2pm/2:30pm, mortgage-rate and discount-rate implications discussed live on Lennar's earnings materials and the next morning's call, then homebuilder-complex repricing to follow. Rezolute's stock reaction is more likely to be driven by any incremental color on the FDA's Type B meeting outcome or the upLIFT trial timeline than by the loss-per-share number itself, which would make the "earnings reaction" more of a pipeline-news reaction wearing an earnings-day label.

Flagged as unverified

Could not confirm the exact intraday stock reaction (percentage move) to Lennar's June delivery-guidance cut, nor current updated figures on Millrose Properties' land-bank size beyond the original ~$6B/105,000-homesite spin-off. Could not find options-implied-move or confirmed short-interest data for Rezolute (beyond the 26.6% figure supplied), Espey, Aeluma (beyond the 27.8% figure supplied), or Sangoma. Could not independently verify Lennar's exact August-quarter incentive rate or whether it moved further from the 12.9% Q2 level — that figure will only be known with Wednesday's release. The precise August retail sales consensus (relevant background for the day, covered in the a.m. note) could not be pinned down from search results due to conflicting figures.

Sources: Yahoo Finance, Lennar newsroom/investor relations, StockTitan, Investing.com, PR Newswire, Fool.com earnings transcripts, Housingwire, CRE Daily, Red Book Lumber Data, Nasdaq.com, CNBC, GlobeNewswire, Seeking Alpha, ClinicalTrialsArena, BioSpace.

Thursday 9/17 a.m. — Desk Preview

Prepared Sunday 9/13/26. Landscape only, no recommendations.

The frame

This is the first full session after Wednesday's FOMC decision, and the tape it opens on is not a normal one. Fed funds futures have been pricing 70-90% odds of a 25bp hike to 3.75-4.00% — a live hike, not a cut, forced by a hot August CPI print (0.4% m/m, 3.4% y/y, core a tenth hot at 0.3%) and Chair Warsh's hawkish Jackson Hole pivot that flipped the September meeting from "hold" to "hike" territory after July's hold carried three dissents in favor of hiking. The 10-year is pressing 5% (4.975% Friday), the S&P closed Friday at 7,656.98 (+65 on the day) with VIX a complacent 15.84, WTI is at $102.43 on the Iran re-escalation, and gold sits at $4,379. Thursday's tape has to digest whatever Warsh said Wednesday afternoon — the statement, the dot plot, and the press conference — before weekly jobless claims (8:30am ET) and the Philly Fed manufacturing index land in the same pre-market window. That is a lot of macro to clear before this week's genuinely thin earnings slate even opens for business, and Friday 9/18 is quad witching, which means Thursday's positioning is also gamma- and pin-risk-aware into a session where index and single-stock options, futures, and single-stock futures all expire simultaneously. Expect thin, headline-driven single-name reactions layered on top of a market that is really trading the Fed.

Tier 1 — before the open

DAVA Endava plc ($2.91, mcap ~$154M) — the clearest AI-vs-outsourced-IT-services print on the calendar, trading at ~3x forward earnings after a 70% collapse from the 52-week high — but the date is more likely 9/22 than Thursday. Yahoo and Nasdaq carry Endava for 9/17; Investing.com and Endava's own release cadence point to Tuesday 9/22, and the company had not announced a date as of Sunday, so treat this as next-week risk that could surprise early. Consensus for the print is EPS $0.10 on revenue of $182M; the read-through only makes sense against what already happened this fiscal year. Endava's fiscal Q3 2026 (reported May 21, quarter ended March 31) missed badly — revenue of £178.5M against a £183.87M consensus, down 8.4% y/y — and the stock fell roughly 20-21% that day. Management cut full-year FY26 guidance sharply on that print: revenue guidance came down to £722-726M from £736-750M, and adjusted EPS guidance was slashed to £0.45-0.49 from £0.80-0.86. For the very quarter in question here, the company's own Q4 FY26 guidance calls for revenue of £181-185M and adjusted diluted EPS of 9-13p — which is roughly what's baked into the consensus figures above. The why matters more than the number: management pointed to Middle East-conflict-related client delays, a broader slowdown in deal cycles, and large outcome-based contracts taking longer to convert, even as the company's AI-native delivery business grew to 15% of revenue in Q3 from 5% a year earlier — the tension between "AI is eating the pipeline" and "AI is also our new growth engine" is the whole story. There is also a corporate-action overlay: Endava has been reported as the subject of management-buyout interest from key shareholders after an earlier private-equity approach to take the company private reportedly fell through — unconfirmed and worth watching for on the call or in the filing. Watch for: whether FY27 initial guidance is offered or deferred, further detail on AI-native revenue mix and margin dilution from the transition, and any commentary on the buyout/strategic-review chatter. This is a foreign private issuer (6-K/20-F filer); the exact reporting date carries real ambiguity — see Flagged as unverified.

VFS VinFast Auto ($3.21, mcap ~$7.51B) — deliveries already reported; the financial print itself has an unusually uncertain date. VinFast already disclosed Q2 2026 delivery volumes: 70,085 EVs globally in the quarter (+96% y/y) and 128,662 EVs for H1 2026 (+78% y/y), alongside a sharp e-scooter/e-bike ramp (286,039 units in Q2, +311% y/y). What has not been delivered is the actual unaudited financial results — the company has said publicly it needs additional time to finalize Q2 numbers because of the late-June 2026 divestment of its Vietnamese manufacturing arm (VinFast Trading and Production JSC) as part of a shift to an asset-light model, and it will announce a results date once that process is complete. Consensus on the sheet is EPS of -$0.33 versus -$0.35 a year ago. The bigger backdrop: FY2025 net losses ran roughly $3.96B with a deeply negative gross margin, and the company's auditors have flagged "substantial doubt" about its ability to continue as a going concern absent continued support; Vingroup and founder Pham Nhat Vuong have committed a combined multi-billion-dollar package of loans, share conversions and personal sponsorship to fund the business toward a stated break-even target by end of 2026. Float is a key mechanical wrinkle here — only roughly 50M of 2.34B shares outstanding are floating, which exaggerates moves in both directions; short interest is a modest 4.7%. Watch for: whether Q2/H1 financials materialize this week at all, updated cash-runway language, and any incremental detail on U.S./Europe/India/Indonesia expansion plans. Given the delivery-vs-financials split, treat the Thursday date itself as unconfirmed — see Flagged as unverified.

IPHA Innate Pharma ($1.87, mcap ~$209M) — confirmed H1 2026 results and business update before the open, call at 8:00am ET. This is a French biotech (foreign private issuer, 6-K filer); consensus on the sheet shows an EPS estimate of -$0.16. The company's Q1 2026 update (reported in May) showed a cash position of roughly €25.4M with runway originally seen only to Q3 2026 — since extended materially by a partnership with Sobi that included a $75M upfront payment, pushing runway out to roughly Q3 2027. The lead program, lacutamab, is being advanced toward a confirmatory Phase 3 trial (TELLOMAK-3) in cutaneous T-cell lymphoma, targeted to start in H2 2026 subject to non-dilutive financing still being negotiated. Watch for: updated cash-runway figures now that the Sobi payment is in hand, confirmation of TELLOMAK-3 trial initiation timing and financing structure, and any regulatory commentary tied to the existing TELLOMAK Phase 2 data package.

The rest, by cluster

Battery/critical-minerals tail: ABAT American Battery Technology ($2.47, mcap ~$337M, short interest 16.4%, 52wk $2.00-$11.49) is calendared by some trackers for a fiscal Q4 print this week, but the company appears to have already reported fiscal Q4 2026 (quarter ended June 30) results back on August 20, with preliminary revenue of $8.2M — matching the revenue estimate on the sheet almost exactly, which suggests the Thursday listing may simply be stale or refer to a 10-K/follow-on filing rather than a fresh earnings release. Separately, and more durably relevant to the name, the DOE reinstated a $115M grant (roughly split $57.7M DOE/$57.7M company cost-share) for ABAT's Tonopah Flats lithium refinery project in June after initially terminating it in October 2025 — the appeal-and-reinstatement arc is the more important open thread for the stock than any single quarter's revenue line.

China EV/fintech tail (thin coverage, foreign filers): KNDI Kandi Technologies ($0.61, mcap ~$61M) and YRD Yiren Digital ($1.01) are both calendared for H1/Q2 China-linked prints this week on some trackers, but neither company's own investor-relations channel could be confirmed with a specific September 17 date in this research pass — treat both as lower-conviction calendar entries.

Where the asymmetries sit

DAVA is the one name here where the setup argues for a genuinely two-sided reaction: a stock already down 70% from its high, trading at roughly 3x forward earnings, has arguably priced in a lot of the AI-cannibalization bear case — but a business still working through client-side deal-cycle elongation and a possible ownership change has real ways to disappoint further, and a "clean" quarter against already-cut guidance could move the stock sharply either direction given how thin the float-adjusted market cap has become. VFS is a different kind of asymmetry — the uncertainty is less about the number and more about whether there's a number at all this week; a surprise release, or continued silence, both carry information. IPHA is the most conventional biotech binary of the morning: the print itself (cash, opex) is secondary to any incremental read on TELLOMAK-3 timing and non-dilutive financing progress.

Dominoes

A hawkish hold-the-line hike from Warsh on Wednesday, confirmed by Thursday morning's price action, keeps the 10-year pressing 5% and keeps pressure on long-duration, cash-burning names — VFS and IPHA both fall into that bucket, as does DAVA given its balance-sheet-light but earnings-power-impaired setup. Weekly jobless claims and the Philly Fed at 8:30am ET Thursday layer a growth read directly on top of the post-FOMC digestion; a soft claims print or a weak Philly Fed alongside a hawkish Fed would be an unusually stagflationary combination for the tape to price in the same morning. Quad witching Friday means Thursday's flows already carry rebalancing and pinning dynamics that can exaggerate single-stock moves on light average daily volume names like DAVA, VFS, and IPHA.

Flagged as unverified

DAVA's exact reporting date carries genuine conflict across sources — Endava's own investor-relations press-release archive (checked directly) does not yet show a confirmed Q4 FY26 announcement date as of this writing, while several secondary earnings-calendar aggregators show September 22, not September 17, as the expected date; the September 17 date should be treated as the desk's working assumption, not a confirmed fact. The management-buyout/going-private chatter for Endava is sourced to a single secondary aggregator and is unconfirmed. VFS's Q2 2026 financial-results date is explicitly unset per the company's own public statements as of the most recent 6-K reviewed; delivery data is confirmed, financial-results timing is not, and Thursday 9/17 should not be assumed. ABAT's fiscal Q4 2026 results (revenue $8.2M) appear to have already been released on August 20, 2026, which conflicts with any calendar listing showing a Thursday 9/17 print for this name — treat that listing as likely stale. KNDI and YRD earnings dates for this week could not be confirmed from either company's own channels in this research pass. IPHA's September 17, 8:00am ET date is corroborated by a company-issued conference-call announcement and is the most solidly confirmed date on this sheet.

Sources: Endava plc investor relations (investors.endava.com); SEC EDGAR 6-K filings for VinFast Auto Ltd. and Endava plc; BioSpace and StockTitan coverage of Innate Pharma's H1 2026 conference-call announcement and Q1 2026 results; Investing.com and Yahoo Finance coverage of Endava's Q3 FY2026 results and guidance cuts; GlobeNewswire and Simply Wall St coverage of ABAT's DOE grant reinstatement; various earnings-calendar aggregators (MarketBeat, TipRanks, Nasdaq, Investing.com, MarketScreener) for date cross-checks, several of which conflicted with one another.

Thursday 9/17 p.m. — Desk Preview

Prepared Sunday 9/13/26. Landscape only, no recommendations.

The frame

By Thursday afternoon the market will have sat with Wednesday's FOMC decision — expected to be a 25bp hike to 3.75-4.00%, Chair Warsh's press conference, and a fresh dot plot — for a full session, plus the morning's weekly jobless claims and Philly Fed data. Whatever direction that combination pushes the S&P (7,656.98 Friday), the 10-year (4.975%, pressing 5%) and the VIX (15.84), the after-the-close book on Thursday is thin — this is the gap week between earnings seasons — which means the handful of names reporting after hours get outsized attention from a market with little else to chew on. That thinness is compounded by Friday 9/18 being quad witching: index and equity options, and index and single-stock futures, all expire simultaneously, so Thursday's after-hours reactions in lightly-traded names can get amplified or partially unwound by Friday's rebalancing flows before they've had time to settle on their own fundamentals.

Tier 1 — after the close

ADSE ADS-TEC Energy ($11.58, mcap ~$871M, 52wk $7.89-$13.50) — battery-buffered EV fast-charging, a direct read on the grid-bottleneck thread. This is an Irish-domiciled foreign private issuer reporting H1 2026 results; the name sits squarely in Carl's power/grid-bottleneck bucket because its core product — battery-buffered charging hardware — exists specifically to let EV fast-chargers deploy on grid connections that can't support full-power draw, which is the binding constraint utilities and site operators are increasingly citing as EV charging buildout collides with AI-data-center power demand in the same interconnection queues. Multiple earnings-calendar sources place ADSE's report on September 16 before the market open rather than Thursday 9/17 after the close — a meaningful discrepancy from this sheet's working calendar that could not be resolved with a company-issued press release in this research pass; see Flagged as unverified. Whichever session it lands in, the read-through items are the same: order backlog and deployment pace for its ADS-TEC charging systems, gross margin trajectory as the company scales from project to production volumes, and any commentary on U.S. grid-interconnection delays as either a headwind (slower site energization) or a tailwind (more demand for buffered solutions that sidestep the queue).

CCL Carnival — likely not this week; the setup is worth sketching anyway given how exposed the name is to this month's macro mix. Carnival's own investor-relations channel has not been found to carry an official Q3 2026 earnings-call announcement, and calendar aggregators are split, with the most specific date found — October 5, 2026 — differing from both this sheet's Thursday 9/17 working assumption and an earlier internal guess of September 28; treat any specific date as unconfirmed (see Flagged as unverified). The setup matters regardless of exactly when it lands: Q3 is Carnival's peak summer booking quarter, with consensus around $1.35 in EPS on roughly $8.39B of revenue, and the stock is trading at $22.75 — within shouting distance of its 52-week low of $22.28 and far from its $34.03 high. The pressure points are fuel and geography: WTI at $102.43 on the Iran re-escalation raises bunker-fuel costs directly, and Carnival carries essentially no fuel-hedging program, so higher oil flows straight through to cost of sales; on top of that, Middle East-linked itinerary disruptions (rerouted or cancelled Red Sea/Eastern Mediterranean sailings) are a repeat theme this cycle. The prior quarter's pattern — a headline beat that the stock nonetheless sold off on — suggests the market is already discounting the revenue line and pricing more on forward booking curve and cost commentary than on the trailing print itself, which is the same dynamic likely to govern whenever the Q3 report actually arrives.

The rest, by cluster

No other names on this sheet's after-the-close calendar for Thursday could be corroborated for this specific date. Hub Group (HUBG) appears on at least one calendar aggregator for Thursday, but the company's normal reporting cadence is late October/November for its next quarterly print, and no company-issued announcement of a September date could be found — this listing looks like a calendar-aggregator error rather than a real event; see Flagged as unverified.

Where the asymmetries sit

ADSE is a small-float, thinly-covered name in a genuinely structural theme (grid-constrained power buildout), which means whatever numbers do print Thursday (or Wednesday, per the conflicting date) carry more information than the market cap alone would suggest — deployment/backlog commentary that confirms accelerating demand from grid-bottlenecked sites would validate the thesis with real data rather than narrative, while a soft print on margins or delayed deployments would hit a stock already mid-range on its 52-week band. CCL's asymmetry, whenever it reports, is now fully a macro-pass-through story: at $100+ oil and with active Middle East disruption, the stock is being priced more on the crude tape and geopolitical headlines than on booking trends, so a genuine de-escalation or a pullback in oil would likely do more for the shares than anything management says on a call.

Dominoes

A hawkish Fed outcome Wednesday that holds the 10-year near or above 5% into Thursday's close keeps pressure on both names here in different ways: ADSE as a small-cap growth story sensitive to discount-rate moves, and CCL as a highly levered, capital-intensive consumer-discretionary name where higher long rates raise the cost of the debt load layered on top of the fuel and geopolitical overhangs. Oil is the more direct lever for CCL specifically — the Iran re-escalation keeping WTI near $102 is doing as much to the stock's setup as anything company-specific. Quad witching Friday is the more mechanical domino: after-hours reactions in a thin Thursday session can see their initial move partially reversed or exaggerated as Friday's options and futures expirations force rebalancing flows through names that otherwise trade on light volume.

Flagged as unverified

ADS-TEC Energy's reporting date is inconsistent across sources: this sheet's working assumption is Thursday 9/17 after the close, but multiple earnings-calendar aggregators (independently of each other) show September 16 before the market open instead; no ADS-TEC-issued press release confirming either date was located in this research pass. Carnival's Q3 2026 earnings date could not be confirmed from the company's own investor-relations channel; the most specific third-party estimate found was October 5, 2026, which differs from both the September 17 working date and an earlier September 28 estimate — Carnival has not been found to have made any official call announcement as of this writing, so treat CCL as probably not reporting this week at all. Hub Group's presence on Thursday's calendar conflicts with its normal late-October/November cadence and could not be corroborated by any company announcement; it is very likely a calendar error rather than a real event.

Sources: SEC EDGAR filings for ADS-TEC Energy plc; TipRanks, Nasdaq, MarketScreener, TradingView and stockanalysis.com earnings-calendar listings for ADSE, CCL and HUBG (several of which conflicted with one another); Investing.com and MarketChameleon coverage of Carnival's Q3 earnings-date estimates; Yahoo Finance market data for underlying prices and 52-week ranges.

Friday 9/18 a.m. — Desk Preview

Prepared Sunday 9/13/26. Landscape only, no recommendations.

The frame

No earnings of consequence are scheduled for Friday — the week's only Friday listing on the calendars checked is a sub-$100M micro-cap (TRT), so the session belongs entirely to the macro tape. It is quad witching (index and single-stock options and futures all expire), the first weekly close after Wednesday's FOMC decision and Chair Warsh's press conference, and the day the S&P quarterly rebalance takes effect at the close. With the 10-year pressing 5%, WTI above $100, and the Fed expected to have delivered its first hike since 2023 two days earlier, Friday's flows are about expiration mechanics, pinning around big strikes, and index-rebalance volume rather than fundamentals. The week's real earnings read-throughs — Lennar's incentive/margin data for the homebuilder complex, Trip.com's China-travel numbers, Dave & Buster's comp trajectory, Forgent's power-equipment backlog — will already be in the tape by then, and next week brings the bigger fiscal-quarter prints (FedEx, General Mills 9/23, Darden 9/24, and Micron — Carl's memory-cycle barometer — later in the month).

Tier 1 — before the open

Nothing to cover. Use the session to reset levels off the post-FOMC ranges.

Dominoes

Whatever the 10-year does into the weekly close sets the starting point for next week's fiscal-quarter reporters, and the homebuilder complex (KBH, TOL, DHI, PHM, NVR, BLDR) will still be repricing Lennar's Wednesday print against the new mortgage-rate level. Quad-witching volume tends to exaggerate moves in names that already gapped on earnings this week.

Flagged as unverified

The Friday calendar was checked on Nasdaq and Yahoo only; any late-added small-cap prints are not reflected. FedEx's fiscal Q1 date was not company-confirmed as of Sunday (trackers vary).

Sources: Nasdaq and Yahoo Finance earnings calendars (viewed 9/13/26); General Mills and Darden company IR date announcements; CME quad-witching calendar.